Market Overview

UPDATE: Piper Jaffray Raises PT to $102 on CR Bard on Higher Large-Cap Multiples

Related BCR
Earnings Scheduled For October 22, 2014
The Lutonix® 035 Drug Coated Balloon Is The First And Only FDA-Approved DCB Available In The U.S. For The Treatment Of Femoropopliteal Occlusive Disease

Piper Jaffray reiterates its Neutral rating on CR Bard (NYSE: BCR) and increases its price target on shares from $92 to $102.

Piper Jaffray notes, "We are raising our price target from $92 to $102/share to incorporate as our new higher median 2012 multiple for large caps (we use 2012 median multiples applied to our 2013 estimates) shifted from 13.0x to 13.6x. We are keeping our FY13 estimate constant at $7.10 EPS. We are also adding $5.40/share to account for a discounted, fully taxed cash benefit from a recent patent infringement ruling (in escrow). We remain Neutral on shares."

BCR closed at $107.83 on Monday.

Latest Ratings for BCR

DateFirmActionFromTo
Dec 2014Wells FargoInitiates Coverage onMarket Perform
Jul 2014CitigroupMaintainsNeutral
Jul 2014JefferiesMaintainsHold

View More Analyst Ratings for BCR
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Reiteration Pre-Market Outlook Analyst Ratings

 

Related Articles (BCR)

Around the Web, We're Loving...

Get Benzinga's Newsletters